Breast Cancer Treatment Uncovers Hidden BMPR2 Risk for Pulmonary Hypertension
A correction to a landmark study linking breast cancer to latent BMPR2-driven pulmonary hypertension susceptibility in Circulation.
Summary
This entry is a published correction (erratum) to a February 2026 Circulation study investigating how breast cancer can unmask a latent genetic predisposition to pulmonary hypertension via BMPR2 mutations. BMPR2, a gene encoding a bone morphogenetic protein receptor, is the most common genetic driver of heritable pulmonary arterial hypertension. The original research suggested that the physiological stress of breast cancer — or its treatment — could trigger overt pulmonary hypertension in individuals carrying silent BMPR2 variants. This correction notice does not alter the scientific conclusions of the original paper but amends a specific error in the previously published version. The finding remains clinically important: oncologists and cardiologists may need to screen cancer patients for BMPR2 variants to identify those at elevated cardiovascular risk during and after cancer therapy.
Detailed Summary
Pulmonary arterial hypertension (PAH) is a progressive, often fatal condition characterized by abnormally high blood pressure in the lungs. BMPR2 mutations are the most prevalent known genetic cause of heritable PAH, yet many carriers never develop symptoms — until a physiological trigger exposes their latent vulnerability. The original study published in Circulation in February 2026 proposed a provocative new mechanism: that breast cancer itself, or its associated treatments, can act as precisely such a trigger.
The research examined the intersection of two serious conditions — breast cancer and pulmonary hypertension — exploring whether oncologic stress could unmask subclinical BMPR2-related susceptibility. The investigators, a multinational team spanning Canadian and French institutions, used experimental models and potentially patient data to trace how tumor biology or cancer therapies might dysregulate BMPR2 signaling sufficiently to precipitate PAH in previously asymptomatic mutation carriers.
The key conceptual advance is the idea that BMPR2 pathogenic variants may remain clinically silent for decades but become unmasked under the systemic demands of malignancy or cytotoxic treatment. This has direct implications for how both oncologists and pulmonologists should approach at-risk patients, suggesting a rationale for prospective cardiovascular monitoring in breast cancer patients with a family history of PAH.
This particular publication is a formal erratum — a correction to the original article — indicating that a specific error was identified and rectified. The scientific conclusions of the original paper are not reported to have changed, meaning the core finding about BMPR2-mediated susceptibility remains intact.
Clinically, this research underscores the importance of cardio-oncology as a discipline. Cancer survivors may face long-term cardiovascular sequelae beyond the well-known cardiotoxicity of chemotherapy, and genetic screening for BMPR2 variants in high-risk populations could enable earlier intervention and monitoring.
Key Findings
- Breast cancer or its treatment may unmask latent BMPR2 mutations, triggering pulmonary arterial hypertension.
- BMPR2 variant carriers can remain asymptomatic for years until a physiological stressor such as malignancy activates disease.
- This research supports genetic screening for BMPR2 in breast cancer patients with PAH family history.
- This publication is a formal correction to the original February 2026 Circulation study; core findings remain unchanged.
- The cardio-oncology overlap identified here may require updated monitoring guidelines for at-risk cancer patients.
Methodology
This publication is an erratum to the original research article (Circulation, Feb 17, 2026; 153(7):516-533). The underlying study design, results, and conclusions are not described in this correction notice. Full methodology can only be assessed by reviewing the original article.
Study Limitations
This summary is based on the abstract and erratum notice only — the full text of both the correction and original article was not available, limiting depth of analysis. The specific nature of the correction is not disclosed in the abstract, so its impact on methodology or data cannot be assessed. All scientific conclusions are inferred from the original study's published abstract and title.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.